Alterations in mitochondrial function in a mouse model of hypertrophic cardiomyopathy

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 284, Issue 2 53-2, 2003, Pages

  Lucas, David T ^a   Aryal, Prafulla ^a   Szweda, Luke I ^b   Koch, Walter J ^c   Leinwand, Leslie A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Mitochondria; Transgenic

Indexed keywords

BETA ADRENERGIC RECEPTOR; CONTRACTILE PROTEIN; CYTOCHROME C OXIDASE; MYOSIN HEAVY CHAIN; OXOGLUTARATE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TROPONIN T;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ELECTRON TRANSPORT; ENZYME ACTIVITY; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENE MUTATION; HEART MITOCHONDRION; HEART MUSCLE OXYGEN CONSUMPTION; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0037307480     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00619.2002     Document Type: Article

References (45)

1. Arbustini E, Diegoli M, Fasani R, Grasso M, Morbini P, Banchieri N, Bellini O, Dal Bello B, Pilotto A, Magrini G, Campana C, Fortina P, Gavazzi A, Narula J, and Vigano M. Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy. Am J Pathol 153: 1501-1510, 1998.
2. Arbustini E, Fasani R, Morbini P, Diegoli M, Grasso M, Dal Bello B, Marangoni E, Banfi P, Banchieri N, Bellini O, Comi G, Narula J, Campana C, Gavazzi A, Danesmo C, and Vigano M. Coexistence of mitochondrial DNA and beta myosin heavy chain mutations in hypertrophic cardiomyopathy with late congestive heart failure [Erratum. Heart 81: Mar, p. 330, 1999]. Heart 80: 548-558, 1998.
3. Balaban RS. Regulation of oxidative phosphorylation in the mammalian cell. Am J Physiol Cell Physiol 258: C377-C389, 1990.
4. 1-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study. Circulation 102: 2070-2075, 2000.
5. Brown GC. Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem J 284: 1-13, 1992.
6. 2+ activation of myofilaments from transgenic mouse hearts expressing R92Q mutant cardiac troponin T. Am J Physiol Heart Circ Physiol 280: H705-H713, 2001.
7. Chien KR. Meeting Koch's postulates for calcium signaling in cardiac hypertrophy. J Clin Invest 105: 1339-1342, 2000.
8. Cho MC, Rapacciuolo A, Koch WJ, Kobayashi Y, Jones LR, and Rockman HA. Defective beta-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression. J Biol Chem 274: 22251-22256, 1999.
9. Cocco T, Di Paola M, Papa S, and Lorusso M. Arachidonic acid interaction with the mitochondrial electron transport chain promotes reactive oxygen species generation. Free Radic Biol Med 27: 51-59, 1999.
10. Cooney GJ, Taegtmeyer H, and Newsholme EA. Tricarboxylic acid cycle flux and enzyme activities in the isolated working rat heart. Biochem J 200: 701-703, 1981.
11. Davey GP and Clark JB. Threshold effects and control of oxidative phosphorylation in nonsynaptic rat brain mitochondria. J Neurochem 66: 1617-1624, 1996.
12. Duchen MR. Contributions of mitochondria to animal physiology: from homeostatic sensor to calcium signalling and cell death. J Physiol 516: 1-17, 1999.
13. Freeman K, Colon-Rivera C, Olsson M, Moore RL, Weinberger H, Grupp I, Vikstrom KL, Iaccarino G, Koch WJ, and Leinwand LA. Cardiac dysfunction and adrenergic signal amnormalities in a transgenic mouse model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 280: H151-H159, 2001.
14. Freeman K, Lerman I, Bohlmeyer T, Iaccarino G, Koch WJ, Lefkowitz RJ, Bristow MR, Kranias EG, and Leinwand LA. Manipulations of cardiac adrenergic signaling and calcium cycling have markedly different effects on the progression of cardiomyopathy. J Clin Invest 107: 967-974, 2001.
15. Gao WD, Perez NG, Seidman CE, Seidman JG, and Marban E. Altered cardiac excitation-contraction coupling in mutant mice with familial hypertrophic cardiomyopathy. J Clin Invest 103: 661-666, 1999.
16. Humphries KM and Szweda LI. Selective inactivation of alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase: reaction of lipoic acid with 4-hydroxy-2-nonenal. Biochemistry 37: 15835-15841, 1998.
17. Humphries KM, Yoo Y, and Szweda LI. Inhibition of NADH- linked mitochondrial respiration by 4-hydroxy-2-nonenal. Biochemistry 37: 552-557, 1198.
18. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K, and Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85: 357-363, 1999.
19. Kish SJ. Brain energy metabolizing enzymes in Alzheimer's disease: alpha-ketoglutarate dehydrogenase complex and cytochrome oxidase. Ann NY Acad Sci 826: 218-228, 1997.
20. Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA, and Lefkowitz RJ. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 268: 1350-1353, 1995.
21. Lucas DT and Szweda LI. Cardiac reperfusion injury: aging, lipid peroxidation, and mitochondrial dysfunction. Proc Natl Acad Sci USA 95: 510-514, 1998.
22. Lucas DT and Szweda LI. Declines in mitochondrial respiration during cardiac reperfusion: age-dependent inactivation of alpha-ketoglutarate dehydrogenase. Proc Natl Acad Sci USA 96: 6689-6693, 1999.
23. Karmazyn M. The 1990 Merck Frosst Award. Ischemic and reperfusion injury in the heart. Cellular mechanisms and pharmacological interventions. Can J Physiol Pharmacol 69: 719-730, 1991.
24. Luo X, Pitkanen S, Kassovska-Bratinova S, Robinson BH, and Lehotay DC. Excessive formation of hydroxyl radicals and aldehydic lipid peroxidation products in cultured skin fibroblasts from patients with complex I deficiency. J Clin Invest 99: 2877- 2882, 1997.
25. Mastrogiacomo F, Bergeron C, and Kish SJ. Brain alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. J Neurochem 61: 2007-2014, 1993.
26. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME, Wang Y, Ross J, Kranias EG, Giles WR, and Chien KR. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99: 313-322, 1999.
27. 2+ homeostasis and disease. Cell Calcium 28: 1-21, 2000.
28. Mizuno Y, Ikebe S, Hattori N, Nakagawa-Hattori Y, Mochizuki H, Tanaka M, and Ozawa T. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. Biochim Biophys Acta 1271: 265-274, 1995.
29. Moreno-Sanchez R, Hogue BA, and Hansford RG. Influence of NAD-linked dehydrogenase activity on flux through oxidative phosphorylation. Biochem J 268: 421-428, 1990.
30. Morii H, Takeuchi Y, and Watanabe Y. Selective inhibition of NADH-CoQ oxidoreductase (complex I) of rat brain mitochondria by arachidonic acid. Biochem Biophys Res Commun 178: 1120-1126, 1190.
31. 2 dependence of diaphragm mitochondrial formation of reactive oxygen species. J Appl Physiol 89: 72-80, 2000.
32. Pitkanen S, Merante F, McLeod DR, Applegarth D, Tong T, and Robinson BH. Familial cardiomyopathy with cataracts and lactic acidosis: a defect in complex I (NADH-dehydrogenase) of the mitochondria respiratory chain. Pediatr Res 39: 513-521, 1996.
33. Robinson BH. Human complex I deficiency: clinical spectrum and involvement of oxygen free radicals in the pathogenicity of the defect. Biochim Biophys Acta 1364: 271-286, 1998.
34. Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ, Ross J Jr., Lefkowitz RJ, and Koch WJ. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA 95: 7000-7005, 1998.
35. 2+ release in heart failure: timing is important. Circ Res 87: 966-968, 2000.
36. Sordahl LA, McCollum WB, Wood WG, and Schwartz A. Mitochondria and sarcoplasmic reticulum function in cardiac hypertrophy and failure. Am J Physiol 224: 497-502, 1973.
37. Tardiff JC, Factor SM, Tompkins BD, Hewett TE, Palmer BM, Moore RL, Schwartz S, Robbins J, and Leinwand LA. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J Clin Invest 101: 2800-2811, 1998.
38. Tardiff JC, Hewett TE, Factor SM, Vikstrom KL, Robbins J, and Leinwand LA. Expression of the β (slow) isoform of MyHC in the adult mouse heart results in dominant functional effects. Am J Physiol Heart Circ Physiol 278: H412-H419, 2000.
39. Tardiff JC, Hewett TE, Palmer BM, Olsson C, Factor SM, Moore RL, Robbins J, and Leinwand LA. Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest 104: 469-481, 1999.
40. Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP, Seidman JG, and Seidman CE. α-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 77: 701-712, 1994.
41. Towbin JA. The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 10: 131-139, 1998.
42. Vikstrom KL, Factor SM, and Leinwand LA. Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy. Mol Med 2: 556-567, 1996.
43. Wallace DC. Mitochondrial diseases in man and mouse. Science 283: 1482-1488, 1999.
44. Watkins H, Seidman JG, and Seidman CE. Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy. Hum Mol Genet 4: 1721-1727, 1995.
45. Zeviani M, Mariotti C, Antozzi C, Fratta GM, Rustin P, and Prelle A. OXPHOS defects and mitochondrial DNA mutations in cardiomyopathy. Muscle Nerve 3: S170-S174, 1995.